Commitments and Contingencies (Details Narrative)								1 Months Ended	3 Months Ended		9 Months Ended
Commitments and Contingencies (Details Narrative)	Jul. 08, 2024 USD ($)	Feb. 23, 2024 USD ($)	Aug. 27, 2023 USD ($)	Jun. 22, 2023 USD ($)	Feb. 05, 2021 USD ($)	Sep. 14, 2015 USD ($)	Dec. 24, 2013 USD ($)	Apr. 30, 2024 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Jan. 31, 2030 USD ($)	Mar. 11, 2025 USD ($)	Dec. 31, 2024 USD ($)	Oct. 04, 2024 EUR (€)	Oct. 03, 2023 EUR (€)	Oct. 08, 2021 EUR (€)
Loss Contingencies [Line Items]
Aggregate commitments expected									$ 292,000		$ 292,000
Research and development costs									50,696	$ 361,630	202,801	$ 691,402
GEIS [Member]
Loss Contingencies [Line Items]
Amount related to milestone payment											685,107
NDA Consulting Corp [Member]
Loss Contingencies [Line Items]
Consulting and advisory fee							$ 4,000		4,000		12,000
Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]
Loss Contingencies [Line Items]
Contractual commitment									510,000		510,000
Clinical Trial Agreements [Member]
Loss Contingencies [Line Items]
Contractual commitment									292,000		292,000
Clinical Trial Monitoring Agreements [Member]
Loss Contingencies [Line Items]
Contractual commitment									218,000		218,000
Aggregate commitments expected									53,000		53,000
Clinical Research Support Agreement [Member] \| City of Hope [Member]
Loss Contingencies [Line Items]
Litigation settlement expense	$ 207,004										0	78,015
Total costs									732,532		732,532
Collaboration Agreement [Member] \| GEIS [Member]
Loss Contingencies [Line Items]
Inventory costs									1,144,000		1,144,000
Aggregate commitments expected									292,000		292,000
Research and development costs									0	0	0	0
Collaboration Agreement [Member] \| Bio Pharma Works LLC [Member]
Loss Contingencies [Line Items]
Consulting and advisory fee						$ 10,000
Reimbursed expense									13,600	8,000	38,400	35,200
Development Collaboration Agreement [Member] \| Netherlands Cancer Institute [Member]
Loss Contingencies [Line Items]
Research and development costs											695,918
Development Collaboration Agreement [Member] \| GEIS [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected														$ 3,095,000
Development Collaboration Agreement [Member] \| Netherlands Cancer Institute [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected \| €																€ 100,000	€ 500,000	€ 391,000
Advance amount related to milestone payment									0	76,278	0	210,362
Clinical Trial Research Monitoring [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									74,000		74,000
Research and development costs									4,942	12,610	16,834	20,838
Work order agreement costs									95,000		95,000
Clinical Trial Research Monitoring [Member] \| MD Anderson Cancer Center Clinical [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									43,597		43,597
Clinical Trial Research Monitoring [Member] \| Theradex Systems, Inc. [Member]
Loss Contingencies [Line Items]
Research and development costs									4,500	14,900	13,500	14,900
Work Order Agreement [Member]
Loss Contingencies [Line Items]
Total costs									61,058		61,058
Aggregate commitments expected									91,000		91,000
Work Order Agreement [Member] \| City of Hope [Member]
Loss Contingencies [Line Items]
Total costs									87,823		87,823
Research and development costs					$ 335,000				0	1,603	0	10,603
Work Order Agreement [Member] \| Theradex Systems, Inc. [Member]
Loss Contingencies [Line Items]
Total costs									33,691		33,691
Research and development costs									3,981	13,475	11,603	26,207
Work cost			$ 106,380	$ 153,000
Percentage of payment through services			47.00%	72.00%
Percentage of payment through software				28.00%
License Agreement [Member]
Loss Contingencies [Line Items]
Non refundable license issue royalty		$ 50,000
Minimum annual royalty payable															$ 30,000
Dosing of product		100,000
Payment for royalties		$ 1,225,000
Royalty percentage		5.00%
License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Non refundable license issue royalty								$ 50,000
License Agreement [Member] \| Due Each January 1 [Member]
Loss Contingencies [Line Items]
Minimum annual royalty payable		$ 25,643						$ 25,643					$ 30,000
Licensing Agreements [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									1,765,000		1,765,000
Research and development costs											97,835
Research and development process costs									7,397	7,537	22,191	68,106
MRI Global [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									84,000		84,000
Research and development costs											382,579
Advance amount related to milestone payment									$ 7,200	$ 9,062	$ 42,057	$ 18,932

LIXTE BIOTECHNOLOGY HOLDINGS, INC. 10-Q